The Expanding Patent Landscape For RNA-Based Therapeutics
The COVID-19 pandemic thrust RNA-based therapeutics into the spotlight. Before that, only a handful had received regulatory approval. Why are...
United States Michaelb Harlin Neal Gerber Eisenberg Kevina Oconnor How Can Developers Alnylam Pharmaceuticals Inc
Source: bioprocessonline.com